Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2021

Pharma News, 2021

Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
Daix (France), Long Island City (New York, United States), September 21, 2021 – Inventiva (Euronext Paris and Nasdaq.
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study Evaluating the Combination of ZEN-3694 and Enzalutamide in mCRPC Patients Who Responded Poorly to Prior Abiraterone
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study Evaluating the Combination of ZEN-3694 and Enzalutamide in mCRPC Patients Who Responded Poorly to Prior Abiraterone
CALGARY, Alberta, Sept.
Pfizer and BioNTech report positive Covid-19 vaccine trial data in children
Pfizer and BioNTech report positive Covid-19 vaccine trial data in children
The vaccine demonstrated a favourable safety profile and was well-tolerated in children aged five to 11 years.
Grifols agrees to acquire Tiancheng Pharmaceutical for $1.3bn
Grifols agrees to acquire Tiancheng Pharmaceutical for $1.3bn
According to the transaction, the equity and enterprise value of Biotest is assessed at $1.
Amgen wins lawsuit against Sandoz and Zydus for Otezla patent
Amgen wins lawsuit against Sandoz and Zydus for Otezla patent
Otezla is approved to treat adults with plaque psoriasis, active psoriatic arthritis and oral ulcers linked with Behçet’s disease.
Oral molnupiravir has at least 350 patients left to recruit in Phase III Covid-19 trial
Oral molnupiravir has at least 350 patients left to recruit in Phase III Covid-19 trial
As breakthrough mild-to-moderate Covid-19 cases continue to rise, all eyes are on Merck and Ridgeback Biotherapeutics’ antiviral.
Samsung Bioepis-Biogen’s biosimilar for Lucentis obtains FDA approval
Samsung Bioepis-Biogen’s biosimilar for Lucentis obtains FDA approval
The US Food and Drug Administration (FDA) has approved Samsung Bioepis and Biogen’s Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab), to treat neov...
World Alzheimer’s Day 2021 September 21
World Alzheimer’s Day 2021 September 21
September 21st every year is World Alzheimer’s Day around the world.
Vumerity Recommended for EU Approval as RRMS Treatment
Vumerity Recommended for EU Approval as RRMS Treatment
A committee of the European Medicines Agency is recommending that Vumerity (diroximel fumarate) be approved as an oral treatment for adults with relapsing-remitting multiple sclerosis (RRM...
Combinations as Another HER2-Targeted Breast Cancer Drug Emerges
Combinations as Another HER2-Targeted Breast Cancer Drug Emerges
NEW YORK – In a Phase III trial of Byondis' (vic-)trastuzumab duocarmazine as a third-line treatment for advanced or metastatic HER2-positive breast cancer, the drug improved progression...
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq.
Hospitalizing the Unvaccinated Has Cost U.S. Nearly $6 Billion
Hospitalizing the Unvaccinated Has Cost U.S. Nearly $6 Billion
THURSDAY, Sept.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand